International Journal of Pharma and Bio Sciences
    ISSN 0975-6299

Int J Pharm Bio Sci Volume 13 Issue 3, July-September, Pages:42-50

A Novel Method for Treating Bronchial Asthma with Newly Designed Histaglobulin Therapy

Sivanandhan K and Dhanalakshmi S

Asthma, a chronic inflammatory disease of the airways is considered as an incurable disease and extensive research is going on in developing novel treatment. The objective of the study is to establish that the antihistamine antibody has low serum histamine binding capacity (SHBC) in allergic patients as compared to normal persons and that it can be raised with our novel method of Histaglobulin treatment thereby effecting a ‘cure’ in bronchial asthma. About 67 normal and 135 allergic persons, were identified based on serum level of total immunoglobulin E (IgE) estimated by ELISA. Antihistamine antibody was separated from serum by affinity chromatography. Presence of antihistamine antibody in the elute was confirmed by SDS-PAGE test. The antihistamine antibody was IgG, confirmed by MALDI-TOF analysis. The SHBC of the antihistamine antibody was estimated based on standard curve, plotted with different concentrations of serum antihistamine antibody by histamine ELISA test. Total Immunoglobulin E and SHBC were estimated in 135 allergic patients. In normal and allergic persons, the total IgE level was <100 IU/ml and 200 IU/ml respectively. The average SHBC of normal persons was 116 µg/ml, which was 39% more as compared to allergic patients whose average SHBC before treatment was 83.6 µg/ml.  135 allergic patients were first subjected to antihistamine, mast cell-membrane stabilizers, anti-inflammatory and bronchodilator drugs followed by histaglobulin injection. The SHBC level was raised in 122 (90.4%) patients to an average of 111.6 µg/ml.  Overall, 132 (97.8%) allergic patients responded well to our treatment and were free from allergic manifestation throughout the follow-up period of about 5 years. Hence, this novel treatment with histaglobulin which has scientific basis, effective and well tolerated can be adopted across the world for effecting a cure from bronchial asthma and allergic rhinitis.

Keywords: Bronchial Asthma, Serum Histamine Binding Capacity, Histaglobulin, Histamine ELISA
Full HTML:


  1. International consensus report on Diagnosis and Treatment of Asthma 1992.
  2. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J. 1996;9(4):687-95. doi: 10.1183/09031936.96.09040687, PMID 8726932.
  3. ISAAC phase 1. Steering committee. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998;12(2):315-35. doi: 10.1183/09031936.98.12020315, PMID 9727780.
  4. Singh S, Yadav R. Bronchial asthma: a global health problem. Int J Pharm Bio Sci. 2016;7(4):163-73. doi: 10.22376/ijpbs.2016.7.4.p163-173.
  5. Burney P. A diet rich in sodium may potentiate asthma. Epidemiologic evidence for a new hypothesis. Chest. 1987;91(6);Suppl:143S-8S. doi: 10.1378/chest.91.6_supplement.143s, PMID 3581956.
  6. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299(6710):1259-60. doi: 10.1136/bmj.299.6710.1259.
  7. Behrendt H, Friedrichs KH, Kramer U, Hitzfled B, Beaker WM, Ring J. The role of indoor and outdoor pollution in allergic diseases. Progr Allergy Clin Immunol. 1995;3:83-9.
  8. Bisgaard H, Li N, Bonnelykke K, et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J Allergy Clin Immunol. 2011;128(3):646:646-52.e1. doi: 10.1016/j.jaci.2011.04.060, PMID 21782228.
  9. McLoughlin RM, Mills KH. Influence of gastrointestinal commensal bacteria on the immune responses that mediate allergy and asthma. J Allergy Clin Immunol. 2011;127(5):1097-107; quiz 1108. doi: 10.1016/j.jaci.2011.02.012, PMID 21420159.
  10. Wood LG, Garg ML, Smart JM, Scott HA, Barker D, Gibson PG. Manipulating antioxidant intake in asthma: a randomized controlled trial. Am J Clin Nutr. 2012;96(3):534-43. doi: 10.3945/ajcn.111.032623, PMID 22854412.
  11. Ninan TK, Russell G. Respiratory symptoms and atopy in Aberdeen school children: evidence from two surveys 25 years apart. BMJ. 1992;304(6831):873-5. doi: 10.1136/bmj.304.6831.873, PMID 1392746.
  12. Rimpelä AH, Savonius B, Rimpelä MK, Haahtela T. Asthma and allergic rhinitis among Finnish adolescents in 1977-1991. Scand J Soc Med. 1995;23(1):60-5. doi: 10.1177/140349489502300111, PMID 7784855.
  13. Peat JK, Salome CM, Woolcoc AJ. Factors associated with bronchial hyper responsiveness in Australian Adults and Children. Eur Respir J. 1992;5:921-9.
  14. Strannegård O, Strannegård IL. In vitro differences between the lymphocytes of normal subjects and atopics. Clin Allergy. 1979;9(6):637-43. doi: 10.1111/j.1365-2222.1979.tb00490.x, PMID 229992.
  15. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med. 2006;354(19):1998-2005. doi: 10.1056/NEJMoa054692, PMID 16687712.
  16. Kips JC, Brusselle GJ, Joos GF, Peleman RA, Tavernier JH, Devos RR et al. Interleukin-12 inhibits antigen-induced airway hyperresponsiveness in mice. Am J Respir Crit Care Med. 1996;153(2):535-9. doi: 10.1164/ajrccm.153.2.8564093.
  17. Sur S, Lam J, Bouchard P, Sigounas A, Holbert D, Metzger WJ. Immunomodulatory effects of IL-12 on allergic lung inflammation depend on timing of doses. J Immunol. 1996;157(9):4173-80. PMID 8892655.
  18. Monahan J, Siegel N, Keith R, Caparon M, Christine L, Compton R, et al. Attenuation of IL-5-mediated signal transduction, eosinophil survival, and inflammatory mediator release by a soluble human IL-5 receptor. J Immunol. 1997;159(8):4024-34. PMID 9378992.
  19. Schafer PH, Wadsworth SA, Wang L, Siekierka JJ. p38 alpha mitogen-activated protein kinase is activated by CD28-mediated signaling and is required for IL-4 production by human CD4+CD45RO+ T cells and Th2 effector cells. J Immunol. 1999;162(12):7110-9. PMID 10358155.
  20. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997;155(6):1828-34. doi: 10.1164/ajrccm.155.6.9196082, PMID 9196082.
  21. Underwood DC, Bochnowicz S, Osborn RR, Kotzer CJ, Luttmann MA, Hay DW, et al. Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig. J Pharmacol Exp Ther. 1998;287(3):988-95. PMID 9864284.
  22. Kumagai K, Ohno I, Okada S, Ohkawara Y, Suzuki K, Shinya T, et al. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol. 1999;162(7):4212-9. PMID 10201949.
  23. Abdallah A, Sanusy K, Said W, Mahran D, Hussin A. Epidemiology of bronchial asthma among preparatory school pupils in Assiut district. Pediatr Allergy Immunol. 2012;10(2):109-17.
  24. Gaur SN, Gupta K, Rajpal S, Singh AB, Rohatgi A et al. Prevalence of bronchial asthma and allergic rhinitis among urban and rural adult population of Delhi. Indian J Allergy Asthma Immunol. 2006;20(2):90-7.
  25. Wilkie AT, Ford RP, Pattemore P, Schluter PJ, Town I, Graham P. Prevalence of childhood asthma symptoms in an industrial suburb of Christchurch. N Z Med J. 1995;108(1000):188-90. PMID 7783986.
  26. Xu X, Wang L. Association of indoor and outdoor particulate level with chronic respiratory illness. Am Rev Respir Dis. 1993;148(6 Pt 1):1516-22. doi: 10.1164/ajrccm/148.6_Pt_1.1516, PMID 8256893.
  27. Sivanandhan K. Epidemiological study of asthma in and around Pollachi [thesis] submitted to Karpagam University; 2011.
  28. Von Mutius E, Martinez FD, Fritzsch C, Nicolai T, Roell G, Thiemann HH. Prevalence of asthma and atopy in two areas of West and East Germany. Am J Respir Crit Care Med. 1994;149(2 Pt 1):358-64. doi: 10.1164/ajrccm.149.2.8306030, PMID 8306030.
  29. Parrot JL, Laborde. Press medicale. 1953;61:1268-9.
  30. Kasimalliah S World Allergy Congress-2007. Poster number 459- Asthma-A Curable disease. Page no. 91, World Allergy Organization.
  31. Global Strategy for Asthma Management and Prevention; 2017. Available from: [cited 27/5/2022].
  32. Høgåsen K, Mollnes TE, Harboe M. Heparin-binding properties of vitronectin are linked to complex formation as illustrated by in vitro polymerization and binding to the terminal complement complex. J Biol Chem. 1992; 15;267(32):23076-82. PMID 1385412.
  33. Mohan J, Saini M, Joshi P. Biophys Biochemica. Acta. 1995;1245:407-13.
  34. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein- dye binding. Anal Biochem. 1976;72:248-54. doi: 10.1006/abio.1976.9999, PMID 942051.
  35. Kirley TL, Norman AB. Unfolding of IgG domains detected by non-reducing SDS-PAGE. Biochem Biophys Res Commun. 2018;503(2):944-9. doi: 10.1016/j.bbrc.2018.06.100, PMID 29932917.
  36. Komatsu E, Buist M, Roy R, Gomes de Oliveira AGG, Bodnar E, Salama A et al. Characterization of immunoglobulins through analysis of N-glycopeptides by MALDI-TOF MS. Methods. 2016;104(104):170-81. doi: 10.1016/j.ymeth.2016.01.005, PMID 26773578.
  37. N KS, N NS, A LB, Y MP. Prevalence of food allergens in different age groups in and around Pollachi, Coimbatore, Tamil Nadu, South India. Int J Pharm Bio Sci. 2017;8(1):652-67. doi: 10.22376/ijpbs.2017.8.1.b652-667.
  38. Summary health statistics for U.S. Children: national health interview survey, 2012, table 2.
  39. Gelfand HH, Cinder JC, Grant SF, Soiffer M Evaluation of histamine-gamma globulin (histaglobin) in the treatment of various allergic conditions. Ann Allergy. 1963;21:150-5. PMID 13947053.
  40. Tanaka A, Lida Y, Sakai K. A Clinical Evaluation of the Therapeutic Efficacy of histobulin. Collect Med Rep Histobulin Igaku SHOBO. 1975:18-20.
  41. Satpathy SN. Role of immunotherapy: histaglobulin in allergic rhinitis. J Pharm Biomed Sci. 2014;4:967-71.
  42. Yamamoto T, Kimura Y, Iwamoto S, et al. Therapeutic Effects of Histobulin- with special reference to bronchial asthma and others. Med Postgraduates. 1979;17(8):545-9.
  43. Asokan NN, Sukumaran EM. Gamma globulin – histamine complex in the treatment of allergic disorder of respiratory tract. Indian Pract. 1982;XXXV(5):171-6.
  44. Matsumura T, Tatene K, Nayajima S. Long- term follow-up study on Histobulin treatment of Bronchial Asthma in Children; Collection of Med. Reports on Histobulin. 1975; 25-8.
  45. Gushchin IS, Luss LV, Il’ina NI, Larina ON, Pakhomova LA. Therapeutic effectiveness of histaglobin preparations in patients with allergic rhinitis and chronic urticaria. Ter Arkh. 1999;71(3):57-62. PMID 10234769.
  46. Narayana J, Shanthi T, Bharadwaj S. Efficacy of histaglobulin on allergic rhinitis. Indian J Otolaryngol Head Neck Surg. 1997;49(1):77-9. doi: 10.1007/BF02991725, PMID 23119262.
  47. Ayoub M, Mittenbühler K, Sütterlin BW, Bessler WG. The anti-allergic drug histaglobin inhibits NF-kappaB nuclear translocation and down-regulates proinflammatory cytokines. Int J Immunopharmacol. 2000;22(10):755-63. doi: 10.1016/s0192-0561(00)00037-0, PMID 10963848.
  48. Parrot JL. Histaminolyse at histaminopesive: actualities pharmacologiques 11th Ser PP. Paris Masson 1958; 233-57.
  49. Landsteiner K. The specificity of serological reactions. Dover Press 1962; Modified by. J Klein. 1982.
  50. Jankowska R, Ma?olepszy J, Nowak I. Influence of histaglobin therapy on skin tests and clinical symptoms in patients with atopic bronchial asthma. Pneumonol Alergol Pol. 1992;60(11-12):69-72. PMID 1284655.
  51. Kaur M, Sharma G, Goel AK, Dewan SP. Clinical efficacy and safety of histaglobulin and fexofenadine in patients with chronic idiopathic urticaria [abstract]. Indian J Pharmacol. 2003;35:195-6.
  52. Dats-Epshte?n MS, Besprozvannaia LF, Bondarenko AA, Dzhansyz IK, Kononova VK. Experience with the use of histaglobulin in the treatment of several allergic diseases. Pediatr Akus Ginekol. 1975;2(2):7-8. PMID 48225.
  53. Mohanty M, Mohapatra S, Pattnaik KP, Swain TR. Prevention of multiple drug allergy by histaglobulin. Indian J Pharmacol. 2006;38(1):68-9. doi: 10.4103/0253-7613.19861.
  54. Noh G. Immunotherapy using Histobulin in atopic dermatitis. Clin Case Rep. 2021;9(1):113-7. doi: 10.1002/ccr3.3472, PMID 33489144.





[Download PDF]
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy
Pharmaceutical Fields
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmaceutics
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Novel drug delivery system
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Nanotechnology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacognosy
© Copyright 2009-2015 IJPBS, India. All rights reserved. Specialized online journals by ubijournal. Website by Ubitech Solutions
         Home I Contact I Terms & Conditions